ArticleIUCrJ2026
High-throughput automated molecular replacement for small-molecule MicroED data.
Article in IUCrJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Interest in electron diffraction (ED) for structural characterization of both proteins and small molecules has grown significantly over the last decade. While ab initio phasing methods remain the gold standard for ED data from small-molecule samples, radiation beam damage during data collection and poor crystallinity of the nanocrystalline sample can make this method unfeasible - particularly for challenging molecules that exhibit conformational flexibility. Molecular replacement (MR) is the most commonly used phasing method for protein ED data and can circumnavigate issues related to diminished data quality. However, its application to small molecules has been limited due to the lack of methods for generating optimal trial conformations. Herein, a high-throughput automated molecular replacement workflow has been developed to solve a novel ED structure of corilagin, a macrocyclic gallotannin with pharmaceutical relevance, which could not be solved with ab initio phasing. The method was validated against three similar macrocycles with known structures (paritaprevir-α, paritaprevir-β and grazoprevir) at varying data resolution limits (1.0, 1.2, 1.4, 1.5, 1.6, 1.8 and 2.0 Å). At all these resolutions for all three structures, the developed workflow was successful and produced solutions with R factors and RMSD values within acceptable limits of the ab initio solved structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.